NCT03542799 (EGFRCART) is a Phase 1 clinical trial of EGFR IL12 CART in Metastatic Colorectal Cancer, sponsored by Shenzhen Second People's Hospital.

Who is sponsoring NCT03542799?

NCT03542799 is sponsored by Shenzhen Second People's Hospital.

What drugs are being tested in NCT03542799?

Interventions in NCT03542799: EGFR IL12 CART.

What condition does NCT03542799 study?

NCT03542799 studies Metastatic Colorectal Cancer.

Is NCT03542799 still recruiting?

NCT03542799 is currently status unknown. Last updated 31 May 2018.

Last reviewed 2018-05-31 · How we verify

NCT03542799: EGFRCART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

Status unknown Phase 1 Last updated 31 May 2018

What this trial tests

Phase 1 trial testing EGFR IL12 CART in Metastatic Colorectal Cancer in 20 participants. Status unknown.

Timeline

22 May 2018

Primary endpoint
23 May 2020

23 May 2021

Quick facts

Lead sponsor	Shenzhen Second People's Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	22 May 2018
Primary completion	23 May 2020
Estimated completion	23 May 2021
Sites	1 location across China

Drugs / interventions tested

EGFR IL12 CART — full drug profile →

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →

Sponsor

Shenzhen Second People's Hospital

Who can join

Adults 18 to 70, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR -IL12 -CART) cells in metastatic patients with colorectal cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cancer stem cell pathways for cancer therapy.
Yang L, Shi P, Zhao G, Xu J, et al · · 2020 · cited 1354× · PMID 32296030 · DOI 10.1038/s41392-020-0110-5
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M, Moon EK. · · 2019 · cited 653× · PMID 30804938 · DOI 10.3389/fimmu.2019.00128
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E, Verschoor CP, Ma GW, Pawelec G. · · 2020 · cited 401× · PMID 32210966 · DOI 10.3389/fimmu.2020.00369
Engineered T Cell Therapy for Cancer in the Clinic.
Zhao L, Cao YJ. · · 2019 · cited 275× · PMID 31681259 · DOI 10.3389/fimmu.2019.02250
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities.
Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, et al · · 2022 · cited 180× · PMID 35434273 · DOI 10.1016/j.omto.2022.03.009
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, et al · · 2023 · cited 142× · PMID 37020537 · DOI 10.3389/fimmu.2023.1113882
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.
Wu B, Shi X, Jiang M, Liu H. · · 2023 · cited 126× · PMID 36810098 · DOI 10.1186/s12943-023-01748-4
The Role of Interleukins in Colorectal Cancer.
Li J, Huang L, Zhao H, Yan Y, et al · · 2020 · cited 109× · PMID 32760201 · DOI 10.7150/ijbs.46651

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Shenzhen Second People's Hospital trials

Trials by the same sponsor.

NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting
NCT05540808 — The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis · unknown
NCT05603975 — Analgesic Effect of Esketamine in DCSB in Adultscontrolled Study · NA · unknown
NCT05465980 — Development and Validation of the Prediction Model for Cognitive Impairment · unknown
NCT05452759 — Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03542799 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Second People's Hospital
Last refreshed: 31 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing